Bioenergy and Breast Cancer: A Report on Tumor Growth and Metastasis.
As many as 80% of the 296,000 women and 2,240 men diagnosed with breast cancer in the United States will seek out complementary and alternative medicine (CAM) treatments. One such therapy is Healing Touch (HT), recognized by the National Center for Complementary and Integrative Health (NCCIH) as a treatment modality. Using a multiple experimental groups design, fifty-six six- to eight-week-old Balb/c mice were injected with 4T1 breast cancer tumor cells and randomly divided into intervention and positive control groups. Five days after tumor cell injection, mice in the intervention groups received HT either daily or every other day for 10 minutes by one HT practitioner. At 15 days after tumor cell injection, tumor size was measured, and metastasis was evaluated by a medical pathologist after necropsy. Tumor size did not differ significantly among the groups (F(3,52) = 0.75, p value = 0.53). The presence of metastasis did not differ across groups (chi-square(3) = 3.902, p = 0.272) or when compared within an organ (liver: chi-square(3) = 2.507, p = 0.474; lungs: chi-square(3) = 3.804, p = 0.283; spleen: chi-square(3) = 0.595, p = 0.898). However, these results did indicate a moderate, though insignificant, positive impact of HT and highlight the need for continued research into dose, length of treatment, and measurable outcomes (tumor size, metastasis) to provide evidence to suggest application for nursing care.
College of Nursing, Montana State University, Bozeman, MT, USA.
Alice
0000-0003-0112-8594
A
Running
Department of Mathematical Sciences, Montana State University, Bozeman, MT, USA.
Mark
M
Greenwood
Department of Mathematical Sciences, Montana State University, Bozeman, MT, USA.
Laura
0000-0002-5517-4601
L
Hildreth
Department of Mathematical Sciences, Montana State University, Bozeman, MT, USA.
Jade
J
Schmidt
J Altern Complement Med. 2002 Oct;8(5):615-21
12470443
Med Arch. 2016 Apr;70(2):142-7
27194823
J Altern Complement Med. 2002 Feb;8(1):33-47
11890432
Am J Chin Med. 2003;31(3):499-507
12943181
J Cancer Surviv. 2011 Mar;5(1):8-17
20924711
Clin J Oncol Nurs. 2007 Feb;11(1):99-113
17441401
Oncogene. 2012 May 17;31(20):2499-511
21963843
N Engl J Med. 2001 Jun 28;344(26):1997-2008
11430330
Clin J Oncol Nurs. 2008 Feb;12(1):113-20
18258581
J Natl Cancer Inst. 2012 Mar 21;104(6):436-8
22393212
Comp Med. 2011 Aug;61(4):339-45
22330249
Explore (NY). 2011 Jan-Feb;7(1):13-26
21194668
Altern Ther Health Med. 2004 May-Jun;10(3):34-41
15154151
Gynecol Oncol. 2011 Nov;123(2):346-50
21864886
Evid Based Complement Alternat Med. 2015;2015:926565
26113869
Integr Cancer Ther. 2002 Dec;1(4):345-70
14664729
Semin Oncol Nurs. 2012 Feb;28(1):10-28
22281307
Nat Rev Cancer. 2001 Oct;1(1):34-45
11900250
Epidemiol Rev. 1993;15(1):220-31
8405206
J Orthop Res. 2008 Nov;26(11):1541-6
18524012
Am J Nurs. 1999 Apr;99(4):43-8
10234323
Brain Behav Immun. 2010 Nov;24(8):1231-40
20600809
J Holist Nurs. 2011 Sep;29(3):221-8
21228402
Forsch Komplementmed. 2011;18(3):146-54
21701183
Oncologist. 2005 Aug;10(7):471-9
16079314
Presse Med. 2007 Dec;36(12 Pt 3):1919-24
17448628
Altern Ther Health Med. 2002 Sep-Oct;8(5):68-70; 72-5
12233805
Clin J Oncol Nurs. 2010 Aug;14(4):E45-55
20682492
Int J Behav Med. 2010 Mar;17(1):1-16
19856109
J Altern Complement Med. 2013 Nov;19(11):876-81
23777242
J Altern Complement Med. 2012 Mar;18(3):221-8
22385045
J Tongji Med Univ. 1991;11(4):253-6
1819037
Int J Biochem Cell Biol. 2006;38(12):2102-13
16893670
J Nurs Scholarsh. 2004;36(2):147-54
15227762